Biomaterials and biotechnology: From the discovery of the first angiogenesis inhibitors to the development of controlled drug delivery systems and the foundation of tissue engineering
This session will cover the contributions of engineering research to the frontiers of healthcare, from bioengineering, to new surgery and imaging techniques to regenerative and personalized medicine. In particular, this talk will examine three areas. The first area is nanotechnology and how it can be potentially used to target drugs to specific sites of the body, such as tumours. We will discuss how nanoparticles can be designed to target them to tumours, including initial human clinical trials. The second area involves novel implantable microchips that can deliver drugs by remote control. Tiny chips can be placed in the body and the release of drugs can be activated by a cell phone or computer. Initial human trials in this area will also be discussed. The third area involves the combination of polymers and mammalian cells to potentially create new tissues such as skin, cartilage or even spinal cords. Human and animal trials will be examined.
By Dr Robert Langer – GGCS health session keynote speaker and panellist
David H. Koch Institute Professor, MIT